Osteopore expands orthopaedic footprint into Hong Kong

Osteopore Limited has entered the Hong Kong orthopaedic market after signing an exclusive distribution agreement with MontsMed Hong Kong Company Limited, extending the company’s regional commercial reach in Asia. The agreement covers the introduction of Osteopore’s custom and off the shelf orthopaedic products into Hong Kong and represents a further step in the company’s international expansion strategy.

Under the agreement, MontsMed will act as the exclusive distributor of Osteopore orthopaedic products in Hong Kong for an initial three year term, with an option to extend by a further year subject to mutual agreement. The initial commercial focus will be on the orthopaedic trauma reconstruction segment, which Osteopore has identified as the area where its bioresorbable implant technology has the highest likelihood of clinical application.

Osteopore develops 3D printed biomimetic implants designed to support natural bone healing. Its technology uses bioresorbable materials that gradually dissolve over time, reducing the need for permanent implants and potentially lowering post surgery complications. The company has previously introduced orthopaedic products into Europe, Singapore and Vietnam and has reported encouraging uptake among surgeons in those markets.

Hong Kong presents a sizeable and active orthopaedic market. According to data published by the Hospital Authority, there were approximately 106,000 new orthopaedic and traumatology cases recorded in 2024. Osteopore views this level of clinical demand as supportive of its initial focus on trauma reconstruction procedures.

Beyond near term sales potential, Hong Kong is regarded by the company as strategically important due to its position as a gateway to mainland China and the Greater Bay Area. Regulatory harmonisation initiatives across the region are aimed at facilitating cross border use of medical devices and encouraging collaboration across healthcare systems, which could support longer term growth opportunities.

Market data cited by the company indicates that the Asia Pacific bone graft and substitutes market was valued at about US 662 million in 2024 and is forecast to grow at a compound annual growth rate of 8.2 percent from 2025 to 2030. Growth is being driven by an ageing population and rising incidence of musculoskeletal injuries and orthopaedic disorders.

Commenting on the announcement, Osteopore chief executive officer Dr Yujing Lim said the Hong Kong expansion forms part of a broader and deliberate commercial execution plan in the region. She said the company was pleased to partner with MontsMed, which has an established presence in the Hong Kong orthopaedic ecosystem and a network of specialist surgeons.

MontsMed chief executive officer Timothy Kong said the company focuses on bringing innovative medical devices to its surgeon network and views Osteopore’s products as well suited to orthopaedic trauma reconstruction and tumour related procedures. He added that MontsMed looks forward to engaging with clinicians on new approaches to bone reconstruction.

The agreement does not disclose financial terms, sales targets or minimum purchase commitments. Osteopore has not provided revenue guidance associated with the Hong Kong launch but has positioned the move as part of a staged expansion across Asia.

With distribution now in place, Osteopore is expected to begin market entry activities in Hong Kong through surgeon engagement and clinical education as it seeks to build adoption within the trauma reconstruction segment .